Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...7172737475767778798081...123124»
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Biomarker, Journal, IO biomarker:  Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. (Pubmed Central) -  Oct 31, 2021   
    The neutrophil-to-lymphocyte ratio is a prognostic factor, along with liver function and tumor markers, in patients with advanced hepatocellular carcinoma who received molecular-targeted agents as primary treatment. Thus, the neutrophil-to-lymphocyte ratio could be a prognostic biomarker for advanced hepatocellular carcinoma primarily treated with immunotherapy.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency. (Pubmed Central) -  Oct 31, 2021   
    In addition, GANT61 reversed the upregulation of CD133 and Hedgehog signalling caused by Lenvatinib in SK-Hep-1 and MHCC97H. Thus, our results suggested that GANT61 reversed Lenvatinib resistance by suppressing Hedgehog signalling in HCC cells, especially in CD133-positive cells and combining Lenvatinib with Hedgehog signalling inhibitors could improve its therapeutic efficacy in HCC patients with high CD133 expression levels.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. (Pubmed Central) -  Oct 31, 2021   
    Thus, our results suggested that GANT61 reversed Lenvatinib resistance by suppressing Hedgehog signalling in HCC cells, especially in CD133-positive cells and combining Lenvatinib with Hedgehog signalling inhibitors could improve its therapeutic efficacy in HCC patients with high CD133 expression levels. LEP index is a promising, easy-to-use tool that may be used to stratify patients undergoing systemic treatment of advanced HCC.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma. (Pubmed Central) -  Oct 31, 2021   
    In 2018, a phase III multinational REFLECT trial on subjects with unresectable HCC (Child-Pugh class A) demonstrated that lenvatinib was non-inferior compared to sorafenib for overall survival, with a controllable toxicity profile, leading to its approval. In addition, our review discusses studies that compare the safety and efficacy profile of lenvatinib especially in patients who have a decline in their liver function to Child-Pugh class B. A current real world analysis of lenvatinib approval for unresectable HCC worldwide is reported.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. (Pubmed Central) -  Oct 30, 2021   
    The newly approved first-line drug donafenib represent the major milestones in HCC therapeutics in recent years...In this review, we summarize the milestones and recent progress in clinical trials of TKIs for HCC therapy. We also provide an overview of the novel nanoparticle-based TKI delivery techniques that enable efficient therapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    KEYNOTE-B99: Phase 2 Study of Pembrolizumab Plus Investigational Agents Combined With Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) (Foyer ABC [VIRTUAL]) -  Oct 29, 2021 - Abstract #ESMOIO2021ESMO_IO_241;    
    P2
    KEYNOTE-B99 (NCT04924101) is a randomized, phase 2, rolling-arm, multicenter open-label study evaluating pembrolizumab plus EP chemotherapy combined with either MK-4830 (an anti-ILT4 antibody), MK-5890 (an anti-CD27 antibody), or lenvatinib as first-line therapy for ES-SCLC...All patients receive 4 cycles of chemotherapy Q3W (etoposide 100 mg/m 2 for 3 days plus cisplatin 75 mg/m 2 or carboplatin area under the concentration-time curve [AUC] 5 mg/mL/min)...Legal entity responsible for the study Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Treatment for liver cancer: From sorafenib to natural products. (Pubmed Central) -  Oct 28, 2021   
    Pleasingly and importantly, there are multiple natural products undergoing clinical evaluation in liver cancer, such as polyphenols like icaritin, resveratrol, and silybin, saponins including ginsenoside Rg3 and glycyrrhizinate, alkaloid containing irinotecan and berberine and inorganic compound arsenic trioxide at present...This article is ended by a perspective remark of futuristic development of natural product-based therapeutic regimen for liver cancer treatment. We expect that this review is an account for current status of natural products as promising anti-liver cancer treatments and should contribute to its understanding.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis. (Pubmed Central) -  Oct 27, 2021   
    The comparable outcomes between the CPA and CPB groups suggest the acceptability of lenvatinib treatment in patients with impaired liver function, at least in the acute phase. With careful follow-up, the dose can be relatively intensified, even in patients with impaired liver function and this may contribute to offering comparable treatment.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (clinicaltrials.gov) -  Oct 27, 2021   
    P2,  N=32, Recruiting, 
    With careful follow-up, the dose can be relatively intensified, even in patients with impaired liver function and this may contribute to offering comparable treatment. Trial completion date: May 2021 --> Jun 2024 | Trial primary completion date: May 2021 --> Jun 2023
  • ||||||||||  Review, Journal:  HCC and Molecular Targeting Therapies: Back to the Future. (Pubmed Central) -  Oct 25, 2021   
    Furthermore, nivolumab, pembrolizumab, and nivolumab plus ipilimumab have been approved by the FDA (2017, 2018, and 2020, respectively). Finally, immune target therapy, cancer vaccines, and epigenetic drugs represent three new possible weapons for the treatment of HCC.
  • ||||||||||  Journal:  Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. (Pubmed Central) -  Oct 22, 2021   
    Since the United States Food and Drug Administration (US FDA) approval of sorafenib in 2008, targeted therapies such as sunitinib, tivantinib, brivanib, erlotinib, and linifanib; monoclonal antibody- bevacizumab showed no meaningful improvement in treatment of HCC...Targeted therapy with lenvatinib, cabozantinib, and regorafenib; monoclonal antibody ramucirumab; immunotherapies nivolumab and pembrolizumab have demonstrated promising results in the clinical trials. The current work outlines the molecular mechanisms and tumorigenesis of HCC, a detailed discussion of the trial results of the approved therapies in HCC, future perspectives and potential options to overcome the challenges of systemic therapy in HCC.
  • ||||||||||  Journal:  Hepatocellular carcinoma, novel therapies on the horizon. (Pubmed Central) -  Oct 22, 2021   
    Combining local and systemic therapies is being actively investigated, as an option for locally advanced disease conventionally treated with locoregional approaches. The horizon remains promising and continues to evolve for HCC a disease long considered with unmet needs.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. (Pubmed Central) -  Oct 22, 2021   
    Sorafenib was the first tyrosine kinase inhibitor (TKI) that showed success in extending survival in patients with advanced hepatocellular carcinoma (HCC)...The current landscape includes other classes of drugs, such as immune checkpoint inhibitors and monoclonal antibodies. The challenge is now placed on how to best select, combine, and sequence drugs with the goal of improving efficacy and minimizing toxicities to deliver better outcomes for HCC patients.
  • ||||||||||  Journal, CAR T-Cell Therapy:  Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. (Pubmed Central) -  Oct 22, 2021   
    In this review article, we focus on the landscape of different immunotherapy strategies in the management of HCC and the combination of checkpoint inhibitors antibodies with antiangiogenics. In addition, we will address the limitation of cell therapies in advanced HCC and current strategies to improve efficacy.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    [VIRTUAL] THE ROLE OF GAS6 / SAXL AS A NOVEL BIOMARKER FOR HEPATOCELLULAR CARCINOMA () -  Oct 21, 2021 - Abstract #AASLD2021AASLD_1416;    
    Serum Gas6 / sAxl levels may be useful as a diagnostic marker, especially in cases of AFP and DCP were negative or in cases of early stage HCC . In addition, serum sAxl levels demonstrated a different changes during sorafenib and lenvatinib administration .
  • ||||||||||  lenvatinib / Generic mfg.
    [VIRTUAL] RESPONDER ANALYSIS OF LENVATINIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA () -  Oct 21, 2021 - Abstract #AASLD2021AASLD_1330;    
    In our population, Sorafenib remains the optimal treatment method based on our findings of a higher progression free survival and overall survival . Achieving an objective response by mRECIST at 4-6 weeks and 8-12 weeks in lenvatinib for unresectable hepatocellular carcinoma contributes to longer OS and is an independent predictor of OS .